Pain News and Research

Latest Pain News and Research

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow to the muscles (claudication).

10 Jan 2011

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Pain Remedies, a subsidiary of Cato BioVentures, announces that a three million dollar grant has been received, to advance its lead development candidate, SP-SAP. Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases, has been awarded a $3 million grant from the National Cancer Institute (NCI).

10 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

Watson receives FDA approval for generic Fentora

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Fentanyl Buccal tablets, USP, in the 0.1, 0.2, 0.4, 0.6 and 0.8 mg strengths, the generic equivalent to Cephalon's Fentora ® tablets.

10 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

Endo Pharmaceuticals receives FDA complete response letter for OPANA ER

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for its new formulation of OPANA® ER designed to be crush resistant.

10 Jan 2011

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Tips for surviving a bout with 'stomach flu'

A post-holiday crush of patients are crowding into area physician offices and hospital emergency rooms as individuals of all ages suddenly find themselves laid low by a highly contagious and quick-striking virus.

10 Jan 2011

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

The U.S. Food and Drug Administration today approved Abstral transmucosal tablets to manage breakthrough pain for adults with cancer.

9 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Study finds combined treatments safe and effective for severe acute pancreatitis

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative treatment, which is in-patient medical treatment.

7 Jan 2011

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

The American Society of Bariatric Physicians (ASBP) is concerned that the FDA advisory panel recommended lowering the BMI requirement for lap-band surgery, while the FDA recently denied two new obesity medications. Bariatric surgery is drastic and expensive and carries higher morbidity and mortality risks than lifestyle interventions or medication. Patients who could have otherwise lost weight in a non-surgical medical bariatric program may now be encouraged to skip medical therapy and jump directly to surgery.

7 Jan 2011

Noninvasive dentistry pioneer develops ZERO-PAIN SmileSimplicity procedure

Noninvasive esthetic dentistry pioneer Dr. Robert Ibsen has developed the ZERO-PAIN SmileSimplicity procedure. Encompassing breakthrough cosmetic and structural restoration techniques, the SmileSimplicity procedure preserves healthy, natural tooth structure.

7 Jan 2011

InHealth awards grant to assess effects of hip replacement therapy on aging populations

The Institute for Health Technology Studies has awarded a grant of $240,000 to an international consortium of researchers, for a study that will assess the effects of hip replacement therapy on the employment and retirement decisions of older adults. Led by researchers at the Universit- Bocconi (Milan), the consortium also includes investigators at the University of York (York, UK), and the Johns Hopkins University School of Public Health (Baltimore).

6 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Study compares treatment cost of PID hospitalizations, ER care for teen girls

Hospitalizing teen girls with pelvic inflammatory disease costs six times as much as treating them in the emergency room, and up to 12 times more than treating them in an outpatient clinic, according to a small study conducted at the Johns Hopkins Children's Center.

6 Jan 2011

Regular eye exams are critical to prevent glaucoma

Glaucoma is the second leading cause of blindness, may strike without symptoms, is not preventable, but it is treatable. During National Glaucoma Awareness Month, The Minnesota Optometric Association (MOA) urges regular eye exams because early detection and treatment is critical to maintain healthy vision and protect the eyes from the effects of glaucoma and other potentially blinding diseases.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Pain News and Research

Latest Pain News and Research

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Watson receives FDA approval for generic Fentora

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Endo Pharmaceuticals receives FDA complete response letter for OPANA ER

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Tips for surviving a bout with 'stomach flu'

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

Infinity provides guidance on anticipated pipeline and business goals for 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Study finds combined treatments safe and effective for severe acute pancreatitis

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

Noninvasive dentistry pioneer develops ZERO-PAIN SmileSimplicity procedure

InHealth awards grant to assess effects of hip replacement therapy on aging populations

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Study compares treatment cost of PID hospitalizations, ER care for teen girls

Regular eye exams are critical to prevent glaucoma

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Pain News and Research

Latest Pain News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in